

**Progesterone Receptor (Clone: PGRP)
Rabbit Monoclonal Antibody**

PRODUCT INFORMATION:

REF	
MR1339	6ml Ready to use
MR1339	3ml Ready to use
MRC1339	1ml Concentrated
MRC1339	0.5ml Concentrated
MRC1339	0.1ml Concentrated
MRH1339	6ml Ready to use
MRH1339	3ml Ready to use

PERFORMANCE CHARACTERISTICS:

Localization: Nucleus
Retrieval Buffer: Tris-EDTA, pH 9.0
Incubation: 30-60 minutes
Positive Control: Breast Ca

SPECIMEN PREPARATION

Staining Recommendations:
 Routinely processed, FFPE tissues are suitable for use with this primary antibody, when using PathnSitu's Poly Excel HRP/DAB detection system. The recommended tissue fixative is 10% neutral buffered formalin. Variable results may occur as a result of prolonged fixation or special processes such as decalcification. The thickness of the sections should be 2-5µm. Slides should be stained once the sections are made as the antigenicity of the cut sections may diminish over a period of time. It is recommended to stain known positive and negative controls simultaneously with unknown specimens.

INTENDED USE

For research use only
 This antibody is intended for use in qualitatively identifying Progesterone Receptor antigens by light microscopy in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemical (IHC) detection methodology. Interpretation of any positive or negative staining must be complemented with the evaluation of proper known controls (Positive and Negative) and must be made within the context of the patient's clinical history and other diagnostic tests. A qualified and trained pathologist must perform an evaluation of the test. This antibody is intended to be used after the primary diagnosis of the tumour has been made by conventional histopathology using nonimmunologic histochemical stains

PRECAUTIONS

1. This product should be used by qualified and trained professional users only
2. The product contains < 0.1% of sodium azide as a preservative and is not classified as hazardous, refer to MSDS for further details
3. As with any product derived from biological sources, proper handling procedures should be used
4. Do not use reagents after the expiration date
5. Use protective clothing and gloves, while handling reagents
6. All hazardous materials should be disposed of according to local state and federal regulations
7. Avoid microbial contamination of reagents as it may lead to incorrect results

SUMMARY AND EXPLANATION

Progesterone is one of the central regulators of female reproduction. In breast development, progesterone is involved in the formation of lobular-alveolar structures and also affects differentiation in the breast by modulation of milk protein synthesis. The cellular effects of progesterone are mediated through progesterone receptors (PR). PR, a protein with 946 amino acids, is a ligand-activated transcription factor member of the steroid receptor superfamily of nuclear receptors. PR is predominantly expressed in female sex steroid-responsive tissues such as the mammary gland, uterus and ovary but is also found in other tissues such as endocrine cells of the Langerhans' islets. The estrogen receptor (ER) and PR status have been used for over 20 years as a predictor of breast carcinoma responsiveness to endocrine therapy and as a prognostic indicator for early recurrence

STAINING PROCEDURE

Antigen Retrieval Solution: Use Tris-EDTA Buffer (Cat#PS009) as an antigen retrieval solution.
Heat Retrieval Method: Retrieve sections under steam pressure for 15 minutes using PathnSitu's MERS (Multi Epitope Retrieval System) for optimal retrieval of the epitopes, allow solution to cool at room temperature, transfer the tissue sections/slides to the distilled water prior to the primary antibody application.
Primary Antibody: Cover the tissue sections with primary antibody and incubate for 30-60 min at room temperature when using PathnSitu's PolyExcel Detection System.
Detection System: Refer to PathnSitu's PolyExcel HRP/ DAB detection system protocol for optimal staining results.

PRINCIPLE OF THE PROCEDURE

The identification of the antigen on the FFPE tissues is carried out using the above-stated antibody. The antigen and antibody complex is visualized using an enzyme-coupled (HRP/AP) secondary antibody with specific binding to the primary antibody, this complex is visualized by the enzymatic activation of the chromogen resulting in a visible reaction production of the antigenic site. Each and every step involves precise time and optimal temperature and the results are interpreted using a light microscope by a qualified and trained pathologist.

QUALITY CONTROL

The recommended positive tissue control for Progesterone Receptor is Breast carcinoma. A positive and negative tissue control must be run with every staining procedure performed to monitor the correct performance of processed tissue and test reagents. A negative tissue control provides an indication of non-specific background staining. If the results are not expected in positive and negative controls the test must be considered invalid and the entire procedure must be cross-verified. The individual laboratory must establish its own quality control to validate the process and antibody when opening a vial.

REAGENT PROVIDED

Concentrated format: Antibody to Progesterone Receptor is affinity purified and diluted in antibody diluent with 1% bovine serum albumin (BSA) and 0.05% of sodium azide (NaN₃).
Recommended dilutions: 1:50 – 1:100
 The antibody dilution and protocol may vary depending on the specimen preparation and specific application. Optimal conditions should be determined by individual laboratories.
Pre-diluted format: PathnSitu's ready-to-use antibodies are pre-titrated to optimal staining conditions. Further dilution will affect the efficacy of the antibody and may yield to sub-optimal staining.
Immunogen: Recombinant protein corresponding to residues within aa400-600 of progesterone receptor was used as an immunogen.
Host, Isotype: Rabbit, IgG

INTERPRETATION OF RESULTS

Progesterone Receptor stains the Nucleus. A qualified experienced/trained pathologist must interpret the results in the patient's sample along with the positive and negative controls.

STORAGE AND HANDLING

Storage Recommendations: Store at 2-8°C. When stored at the appropriate conditions, the antibody is stable until expiry. Do not use the antibody after the expiration date provided on the vial in any condition.
 To ensure proper reagent delivery and stability, replace the dispenser cap after

PERFORMANCE CHARACTERISTICS

PathnSitu products will undergo a thorough quality control check before it is released to the market. The antibody showed consistent specific and sensitive staining on the multiple positive tissue controls tested, by inter-run, intra run and lot-based studies. The antibody is stable for the expiry mentioned on the labels which is determined by real-time or accelerated methods.

TROUBLESHOOTING

1. Follow the antibody-specific protocol recommendations according to the datasheet provided
2. Tissue staining is dependent on the handling and processing of the tissue prior to staining. Improper fixation, tissue processing, antibody freezing and thawing, washing, drying, heating, sectioning or contamination with other

tissues or fluids may produce artefacts, antibody trapping or inaccurate results

3. Do not allow the section to dry out during the entire IHC process
4. Excessive or incomplete counterstaining may compromise the interpretation of the results
5. If unusual results occur, contact PathnSitu's Technical Support at +91-40-2701 5544 or E-mail: techsupport@pathnsitu.com

LIMITATIONS AND WARRANTY

Authorized and skilled/trained personnel only may use the product. The clinical interpretation of any test results should be evaluated within the context of the patient's medical history and other diagnostic test results. A qualified trained pathologist must perform the evaluation of the test results. There are no warranties, expressed or implied, which extend beyond the description. PathnSitu is not liable for property damage, personal injury, time or effort or economic loss caused by this product.

BIBLIOGRAPHY

1. Bardou V-J, Arpino G, Elledge RM, et al. J Clin Oncol 2003;21:1973-1979.
2. Elledge RM, Green S, Pugh R et al. Int J Cancer 2000;89:111-117.

EXPLANATION OF SYMBOLS

LOT

Lot number / Batch number



Expiry

RUO

Research use only



Storage limitation



Date of manufacture

REF

Catalogue number